Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction

NACompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

October 4, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Neurogenic BladderLower Urinary Tract SymptomsOveractive BladderNeuro: Neurogenic BladderNeurogenic Detrusor Overactivity
Interventions
PROCEDURE

Standard number of injection sites

200 units or 300 units BTX-A reconstituted in 20 mL normal saline, injected into the bladder detrusor in 20 separate injections of 1 mL including the trigone.

PROCEDURE

Reduced number of injection sites

200 units or 300 units BTX-A reconstituted in 5 mL normal saline, injected into the bladder detrusor in 5 separate injections of 1 mL including the trigone.

Trial Locations (1)

77030

Houston Methodist Hospital, Houston

All Listed Sponsors
collaborator

Collaborating for Advancement of Interdisciplinary Research in Benign Urology

UNKNOWN

lead

The Methodist Hospital Research Institute

OTHER

NCT06059066 - Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction | Biotech Hunter | Biotech Hunter